Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Conclusions/interpretationWhen included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes.Trial registrationClinicalTrials.gov NCT03590626FundingThe current study was supported by an investigator-initiated study grant from Medanta –The Medicity’s departmental research fund and a grant from the Endocrine and Diabetes Foundation (EDF), India.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research